Brand Name
Zunveyl
Generic Name
Benzgalantamine
View Brand Information FDA approval date: August 09, 2024
Form: Tablet
What is Zunveyl (Benzgalantamine)?
ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
Summary: The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.